Overview

Adherence in Topical Treatment of Psoriasis

Status:
Completed

Trial end date:
2017-08-29

Target enrollment:
0

Participant gender:
All

Summary

Medical adherence to topical corticosteroid products in psoriasis patients is a main determinant for poor treatment effect. The investigators aim to test if a multifaceted intervention delivered in an app (MyPso QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM) (Teslo) can improve medical adherence among psoriasis patients treated with a topical calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©). The study is classified as a phase 4 study, since it is studied if improved use of Enstilar© results in improved treatment outcomes. Link to published study protocol: https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3 Link to published results from the study: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16667

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Odense University Hospital

Treatments:

Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene

Criteria

Inclusion Criteria:

- Psoriasis patients aged 18-75 years with mild-moderate psoriasis. It is mandatory that
patients have a smartphone and basic skills for use of the smartphone.

Exclusion Criteria:

- aged under 18 and above 75 years, guttate psoriasis, severe degree of psoriasis, i.e.
pustular and erythrodermic psoriasis, lack of smartphone and user skills for the
smartphone